ycoside antibiotics, ethacrynic acid, or other ototoxic drugs. if the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4mg furosemide per minute has been used) (see precautions: drug interactions ).

tion and laboratory monitoring are particularly advisable (see precautions: laboratory test ). geriatric patients --in general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range (see precautions: geriatric use ). pediatric patients --the usual initial dose of oral furosemide in pediatric patients is 2 mg/kg body weight, given as a single dose. if the diuretic response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. doses greater than 6 mg/kg body weight are not recommended. for maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level. hypertension therapy should be individualized according to the patient's response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response. adults --the usual initial dose of furosemide for hypertension is 80mg, usually divided into 40mg twice a day. dosage should then be adjusted according to response. if response is not satisfactory, add other antihypertensive agents. changes in blood pressure must be carefully monitored when furosemide is used with other antihypertensive drugs, especially during initial therapy. to prevent excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50% when furosemide is added to the regimen. as the blood pressure falls under the potentiating effect of furosemide, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary. geriatric patients --in general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range (see precautions: geriatric use ).

ystemic symptoms 5.acute generalized exanthematous pustulosis 6.exfoliative dermatitis 7.bullous pemphigoid 8.purpura 9.photosensitivity 10.rash 11.pruritis 12.urticaria cardiovascular reaction 1. orthostatic hypotension may occur and be aggravated by alcohol, barbiturates, or narcotics. 2. increase in cholesterol and triglyceride serum levels other reactions 1.hyperglycemia 6. restlessness 2.glycosuria 7.urinary bladder spasm 3.hyperuricemia 8.thrombophlebitis 4.muscle spasm 5.weakness 9. fever whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn. to report suspected adverse reactions, contact graviti pharmaceuticals, inc., 1-855-298-4506 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

al administration is within 1 hour. the peak effect occurs within the first or second hour. the duration of diuretic effect is 6 to 8 hours. in fasted normal men, the mean bioavailability of furosemide from furosemide tablets and furosemide oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug. although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. the terminal half-life of furosemide is approximately 2 hours. significantly more furosemide is excreted in urine following the iv injection than after the tablet or oral solution. there are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine. geriatric population furosemide binding to albumin may be reduced in elderly patients. furosemide is predominantly excreted unchanged in the urine. the renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically significantly smaller than in younger healthy male subjects (20 to 35 years of age). the initial diuretic effect of furosemide in older subjects is decreased relative to younger subjects (see precautions: geriatric use ).

�f (20° to 25°c); excursions permitted to 59° to 86°f (15° to 30°c) [see usp controlled room temperature]. manufactured for: graviti pharmaceuticals inc., wilmington, delaware – 19801, usa. manufactured by: graviti pharmaceuticals pvt. ltd. telangana-502307, india. made in india revised: july 2022